Nektar Therapeutics Deferred Compensation Arrangement with Individual, Employer Contribution (Deprecated 2017-01-31)
Nektar Therapeutics (NKTR) reported Deferred Compensation Arrangement with Individual, Employer Contribution (Deprecated 2017-01-31) of $3.00 thousand for the 12-month period ending 2013-12-31, per its 10-K filed 2014-02-27.
Discontinued › Expense Statement › Operating Expenses
us-gaap:DeferredCompensationArrangementWithIndividualEmployerContribution · last filed 2014-02-27
- Nektar Therapeutics deferred compensation arrangement with individual, employer contribution (deprecated 2017-01-31) for fiscal 2013 was $3.00K, a 0.00% change from fiscal 2012.
- Nektar Therapeutics deferred compensation arrangement with individual, employer contribution (deprecated 2017-01-31) for fiscal 2012 was $3.00K, a 0.00% change from fiscal 2011.
- Nektar Therapeutics deferred compensation arrangement with individual, employer contribution (deprecated 2017-01-31) for fiscal 2011 was $3.00K.
| Period end | Deferred Compensation Arrangement with Individual, Employer Contribution (Deprecated 2017-01-31) 12 month |
|---|---|
| 2013-12-31 | $3.00K 10-K · filed 2014-02-27 |
| 2012-12-31 | $3.00K 10-K · filed 2013-03-01 |
| 2011-12-31 | $3.00K 10-K · filed 2012-02-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |